Endothelin Receptor Antagonists
"Endothelin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.
Below are MeSH descriptors whose meaning is more general than "Endothelin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Endothelin Receptor Antagonists".
This graph shows the total number of publications written about "Endothelin Receptor Antagonists" by people in this website by year, and whether "Endothelin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Endothelin Receptor Antagonists" by people in Profiles.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937.
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clin Pharmacol Ther. 2022 Nov; 112(5):1098-1107.
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Cancer Lett. 2022 09 28; 544:215801.
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident?Heart?Failure. JACC Heart Fail. 2022 07; 10(7):498-507.
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Dec 01; 192(11):1345-54.
Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Jun; 12(6):960.
Endothelin antagonism and hypertension: an evolving target. Semin Nephrol. 2015 Mar; 35(2):168-75.
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Feb; 12(2):269-73.